KPTI
Karyopharm Therapeutics Inc.
$8.64
-2.37%
2026-05-08
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Key Fundamentals
Forward P/E
-2.02
EPS (TTM)
$-17.93
Revenue Growth (YoY)
11.6%
Profit Margin
-134.2%
Beta
0.81
Market Cap
$199.2M
Avg Volume (10D)
265K
Recent Breakout Signals
No recent breakout signals detected for KPTI.
Recent Price Range (60 Days)
60D High
$10.99
60D Low
$5.00
Avg Volume
997K
Latest Close
$8.64
Get breakout alerts for KPTI
Sign up for Breakout Scanner to receive daily notifications when KPTI triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Karyopharm Therapeutics Inc. (KPTI) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors KPTI daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. KPTI operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.